Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
Hajime YamakageMasashi TanakaTakayuki InoueShinji OdoriToru KusakabeNoriko Satoh-AsaharaPublished in: Journal of diabetes investigation (2019)
Dapagliflozin add-on therapy in patients with type 2 diabetes reduced myostatin levels significantly and maintained SMM, without significant changes in FGF21 levels.
Keyphrases